Tuesday, September 16, 2025 9/16/2025

1/6 HBCD Prenatal Experiences and Longitudinal Development (PRELUDE) Consortium

Award Number: U01DA055352
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2021
PERIOD OF PERFORMANCE END DATE: 06/30/2026

Group Awards By:

View Award Description

1/6 HBCD Prenatal Experiences and Longitudinal Development (PRELUDE) Consortium - Neurodevelopmental processes are shaped by dynamic interactions between genes and environments. Maladaptive experiences early in life can alter developmental trajectories, leading to harmful and enduring developmental sequelae. Pre- and postnatal hazards include maternal substance exposure, toxicant exposures in pregnancy and early life, maternal health conditions, parental psychopathology, maltreatment, and excessive stress. To elucidate how various environmental hazards impact child development, it is imperative that a normative template of developmental trajectories over the first 10 years of life be established based on a sufficiently large and demographically heterogeneous sample of the US population. To accomplish this, the Healthy Brain and Child Development (HBCD) Consortium has been formed to deploy a harmonized, optimized, and innovative set of neuroimaging (MRI, EEG) measures complemented by an extensive battery of behavioral, physiological, and psychological tools, and biospecimens to understand neurodevelopmental trajectories in a sample of 7,200 mothers and infants enrolled at 27 sites across the United States (US). The HBCD Study will carry out a common research protocol under direction of the HBCD Consortium Administrative Core (HCAC) and will assemble and distribute a comprehensive and well-curated research dataset to the scientific community at large under the direction of the HBCD Data Coordinating Center (HDCC). The overarching goal of the HBCD Study is to create a comprehensive, harmonized, and high-dimensional dataset that will characterize typical neurodevelopmental trajectories in US children and that will assess how biological and environmental exposures affect those trajectories. A special emphasis will be placed on understanding the impact of pre- and postnatal exposure to opioids, marijuana, alcohol, tobacco and/or other substances. To address these broad objectives, the sample of women enrolled will include: 1) a varied cohort that is representative of the US population; 2) pregnant woman with use of targeted substances (opioids, marijuana, alcohol, tobacco); and 3) demographically and behaviorally similar women without substance use in pregnancy to enable valid causal inferences. In addition, the HBCD Study will identify key developmental windows during which both harmful and protective environments have the most influence on later neurodevelopmental outcomes. The large, multi-modal, longitudinal, and generalizable dataset that will be produced for the first time by this study will provide novel insights into child development using state-of-the-art methods. The HBCD Study will inform public policy to improve the health and development of children across the nation.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $2,478,085 )
2025	2025	ARKANSAS CHILDREN'S RESEARCH INSTITUTE	13 CHILDREN'S WAY	LITTLE ROCK	AR	72202	PULASKI	USA	Drug Use and Addiction Research Programs	001	5	8/22/2025	NON-COMPETING CONTINUATION	$516,630
2025	2025	ARKANSAS CHILDREN'S RESEARCH INSTITUTE	13 CHILDREN'S WAY	LITTLE ROCK	AR	72202	PULASKI	USA	Drug Use and Addiction Research Programs	000	5	8/7/2025	NON-COMPETING CONTINUATION	$1,961,455
														Subtotal = $2,478,085

Issue Date FY: 2024 ( Subtotal = $2,759,499 )
2024	2024	ARKANSAS CHILDREN'S RESEARCH INSTITUTE	13 CHILDREN'S WAY	LITTLE ROCK	AR	72202	PULASKI	USA	Drug Use and Addiction Research Programs	001	4	8/28/2024	NON-COMPETING CONTINUATION	$520,076
2024	2024	ARKANSAS CHILDREN'S RESEARCH INSTITUTE	13 CHILDREN'S WAY	LITTLE ROCK	AR	72202	PULASKI	USA	Drug Use and Addiction Research Programs	000	4	7/17/2024	NON-COMPETING CONTINUATION	$2,239,423
														Subtotal = $2,759,499

Issue Date FY: 2023 ( Subtotal = $2,091,360 )
2023	2023	ARKANSAS CHILDREN'S RESEARCH INSTITUTE	13 CHILDREN'S WAY	LITTLE ROCK	AR	72202	PULASKI	USA	Drug Use and Addiction Research Programs	001	3	7/20/2023	SUPPLEMENT FOR EXPANSION	$438,476
2023	2023	ARKANSAS CHILDREN'S RESEARCH INSTITUTE	13 CHILDREN'S WAY	LITTLE ROCK	AR	72202	PULASKI	USA	Drug Use and Addiction Research Programs	002	3	7/28/2023	NON-COMPETING CONTINUATION	$0
2023	2023	ARKANSAS CHILDREN'S RESEARCH INSTITUTE	13 CHILDREN'S WAY	LITTLE ROCK	AR	72202	PULASKI	USA	Drug Use and Addiction Research Programs	000	3	6/28/2023	NON-COMPETING CONTINUATION	$1,652,884
														Subtotal = $2,091,360

Issue Date FY: 2022 ( Subtotal = $1,609,306 )
2022	2022	AR CHILDRENS HOSPITAL RESEARCH INSTITUTE	13 CHILDRENS WAY STE 842	LITTLE ROCK	AR	72202	PULASKI	USA	Drug Use and Addiction Research Programs	001	2	7/7/2022	NON-COMPETING CONTINUATION	$1,609,306
2022	2022	ARKANSAS CHILDREN'S RESEARCH INSTITUTE	13 CHILDREN'S WAY	LITTLE ROCK	AR	72202	PULASKI	USA	Drug Use and Addiction Research Programs	002	2	8/23/2022	NON-COMPETING CONTINUATION	$0
2022	2021	AR CHILDRENS HOSPITAL RESEARCH INSTITUTE	13 CHILDRENS WAY STE 842	LITTLE ROCK	AR	72202	PULASKI	USA	Drug Use and Addiction Research Programs	000	1	5/5/2022	NEW	$0
														Subtotal = $1,609,306

Issue Date FY: 2021 ( Subtotal = $911,400 )
2021	2021	AR CHILDRENS HOSPITAL RESEARCH INSTITUTE	13 CHILDRENS WAY STE 842	LITTLE ROCK	AR	72202	PULASKI	USA	Drug Use and Addiction Research Programs	000	1	9/24/2021	NEW	$911,400
														Subtotal = $911,400

Grand Total All Awards = $9,849,650

Top

All Categories

About

Search

Reports

Data Submission

Award Information

1/6 HBCD Prenatal Experiences and Longitudinal Development (PRELUDE) Consortium

Award Number: U01DA055352

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2021

PERIOD OF PERFORMANCE END DATE: 06/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer